As multiple MCP-1 inhibitors are currently being developed and tested in clinical trials for cancer and autoimmune diseases(47), these medications could be repurposed for AD intervention and prevention in allele carriers of NAV3 rs696468-CC and UNC5C rs72659964-AT + TT with peripheral inflammation. This evidence concerns the gene NAV3 and cancer.